Myeloma

Bisphosphonates in Myeloma (Multiple Myeloma) V1.0

Bortezomib & Dexamethasone (Vel/Dex) Multiple Myeloma V1.0

Bortezomib, Melphalan & Prednisolone (VMP) Multiple Myeloma V1.0

Carfilzomib Lenalidomide and Dexamethasone Multiple Myeloma V1.0

CTDa – Cyclophosphamide, Thalidomide & Dexamethasone (attenuated) Multiple Myeloma Protocol V1.0

CTD – Cyclophosphamide, Thalidomide & Dexamethasone Multiple Myeloma Protocol V1.0

CVD – Cyclophosphamide, Bortezomib & Dexamethasone Full Dose Protocol Amyloidosis V1.1

CVD - Cyclophosphamide, Bortezomib and Dexamethasone Intermediate Dose Protocol Amyloidosis V1.1

CVD - Cyclophosphamide, Bortezomib and Dexamethasone Low Dose Protocol Amyloidosis V1.1

Cyclophosphamide Myeloma Protocol V1.1

Daratumumab Bortezomib Thalidomide and Dexamethasone MYELOMA V1.0

Daratumumab (Subcutaneous) Monotherapy Myeloma V1.1

DRd Daratumumab, Lenalidomide & Dexamethasone Multiple Myeloma V1.0

DVd - Daratumumab (Subcutaneous), Bortezomib & Dexamethasone Myeloma V1.1

DTPACE Multiple Myeloma or Plasma Cell Leukaemia V2.0

Isatuximab with Pomalidomide and Dexamethasone Multiple Myeloma Protocol V1.0

Intravenous Cyclophosphamide Myeloma V1.0

Ixazomib, Lenalidomide & Dexamethasone Multiple Myeloma Protocol V1.1

Lenalidomide, Cyclophosphamide & Dexamethasone Multiple Myeloma V1.0

Lenalidomide & Dexamethasone Multiple Myeloma Protocol V1.2

Maintenance Lenalidomide after Autologous Stem Cell Transplant - Multiple Myeloma Protocol V1.0

Modified PAD (Bortezomib Doxorubicin Dexamethasone Relapsed Refractory Multiple Myeloma V1.0

MPT Melphalan, Prednisolone & Thalidomide Myeloma V1.0

Oral Melphalan and Prednisolone MYELOMA V1.0

Panobinostat, Bortezomib and Dexamethasone Multiple Myeloma V1.0

Pomalidomide & Dexamethasone Multiple Myeloma Protocol V1.1

TECLISTAMAB (JNJ-64007957) Relapsed & Refractory Multiple Myeloma Via Managed Access Program V2.0

VCD – Bortezomib, Cyclophosphamide & Dexamethasone Multiple Myeloma Protocol V1.0

V-DTPACE Myeloma Protocol V2.0

VTD – Bortezomib, Thalidomide & Dexamethasone Multiple Myeloma Protocol V1.1

Home
About the Centre
- About the Centre
- The Clatterbridge Cancer Centre
  - The Clatterbridge Cancer Centre
  - CCC-Liverpool
  - CCC-Wirral
  - CCC-Aintree
  - Networked services
  - Paddington Community Diagnostic Centre
- Our expertise
  - Our expertise
  - Our Standards
- Research and Innovation
- Education and Training
- Our strategies and plans
  - Our strategies and plans
  - Our Green Plan: Creating a Greener CCC
- Corporate matters
  - Corporate matters
  - Trust board members
  - Council of Governors
  - Meetings
  - Performance reports
  - Public documents
  - The CCC Staff Excellence Awards
- Access to information
  - Access to information
  - Freedom of Information (FOI)
  - Publication Scheme
- Equality, Diversity and Inclusion
  - Equality, Diversity and Inclusion
  - Being Inclusive - videos & stories
- Media enquiries and social media
- History of The Clatterbridge Cancer Centre
- Arts at The Clatterbridge Cancer Centre
  - Arts at The Clatterbridge Cancer Centre
  - Environment
  - Arts activities
  - Music
For Patients
For Professionals
- For Professionals
- Working at the Centre
  - Working at the Centre
  - Working at the Centre
  - Why work for us?
  - Staff Benefits
  - Working in Wirral and Liverpool
  - Current job vacancies
  - Staff Privacy Notice
  - Staff profiles
- Research
- Education and courses
- Guidance
- Physics Department
  - Physics Department
  - Radiotherapy Physics
  - Imaging Physics
  - Eye Proton Therapy
  - Physics Research
  - External Professional Activities
- Clinical referral
  - Clinical referral
  - Metastatic Spinal Cord Compression (MSCC)
- Oncology Pharmacy
  - Oncology Pharmacy
  - Production of sterile chemotherapy products
  - Isolators
  - Ward pharmacy service
Support us
- Support us
- Membership
  - Membership
  - Become a member
  - Frequently Asked Questions
- Volunteering
- Fundraising
Clatterbridge Private Clinic
PharmaC